Interestingly, co-expression of Tim-3 with PD-1 usually typically predicts T-cell exhaustion and loss of stemness [100], and combined blockade of Tim-3 and PD-1 has been shown to restore effector T-cell function, produce stronger tumor regression and an enhanced anti-tumor immune response compared to single agent therapies [101]. The gene discussed is HAVCR2; the disease is neoplasm.